Publication date: Sep 09, 2019
Lewy body disease (LBD) is characterized by the presence of Lewy bodies (LBs) and Lewy neurites and comprises a diagnostic spectrum that includes Parkinson’s disease (PD), PD with dementia, and dementia with LBs. LBs and Lewy neurites are insoluble aggregates composed mainly of phosphorylated α-synuclein and can be widely distributed throughout the central and peripheral nervous systems. The distribution of LBs may determine the LBD phenotype. Braak hypothesized that Lewy pathology progresses ascendingly from the peripheral nervous system to the olfactory bulbs and brainstem and then to other brain regions. Braak’s PD staging suggests that LBD is a prion-like disease. Most typical PD cases fit with Braak’s PD staging, but the scheme fails in some cases. Alzheimer’s disease, progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy, frontotemporal lobar degeneration, Creutzfeldt-Jakob disease, cerebrovascular diseases, and essential tremor are common misdiagnoses for pathologically confirmed LBD. LBD exhibits considerable heterogeneity in both clinical and pathological settings, which makes clinical diagnosis challenging.
Kon, T., Tomiyama, M., and Wakabayashi, K. Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. 22233. 2019 Neuropathology.
|disease||DOID||frontotemporal lobar degeneration|
|disease||MESH||frontotemporal lobar degeneration|
|disease||DOID||multiple system atrophy|
|disease||MESH||multiple system atrophy|
|disease||DOID||progressive supranuclear palsy|
|disease||MESH||progressive supranuclear palsy|
|disease||DOID||Lewy body disease|
|disease||MESH||Lewy body disease|
- Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy.
- Alzheimer’s disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview.
- PDGeneration: Mapping the Future of Parkinson’s Disease